Tibotec launches Intelence in the UK
This article was originally published in Scrip
Tibotec Pharmaceuticals (Johnson & Johnson) has announced the UK launch of Intelence (etravirine), an antiretroviral drug of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, for use in treatment-experienced adults in combination with a boosted protease inhibitor and other antiretrovirals. Trial data suggest that in the presence of common NNRTI mutations in NNRTI-resistant patients, Intelence retains activity. Intelence is the first new NNRTI on the market in approximately 10 years. It was approved by the European Commission in August and by the US FDA in January (Scrip Online, January 23rd, 2008). The cost of Intelence is expected to be £319.82 per month.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.